May 09, 2019 - Oral semaglutide is on its way.
May 17, 2019 - Top Gainers: GILD +3.1%. NOG +3.2%. NBRV +2.7%. GOL +2.3%. NIO +1%.Top Losers: LTM -4.7%. SIGA -1.9%. NKTR -1.8%. NVO -1.7%. ZYNE -1.7%.
Aug 27, 2015 - Novo Nordisk (NVO) announced that it intends to start the phase IIIa PIONEER program on once-daily oral semaglutide for the treatment of type II diabetes.
Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
Sep 02, 2015 - Bristol-Myers Squibb Company (BMY) and its partner AbbVie (ABBV) announced that the BLA for Empliciti has been accepted with priority review by the FDA.
Sep 09, 2015 - Novo Nordisk (NVO) Sees Hammer Chart Pattern: Time to Buy?
May 01, 2016 - Novo Nordisk A/S (NYSE:NVO) Q1 2016 Earnings Conference Call April 29, 2016, 07:00 ET Executives Lars Rebien Sorensen - CEO Mads Krogsgaard Thomsen - Chief Science Officer Jesper Brandgaard - CFO Jako
Aug 05, 2016 - Novo Nordisk A/S (NYSE:NVO)Q2 2016 Earnings CallAugust 05, 2016 7:00 am ETExecutivesLars Rebien Sørensen - President & Chief Executive OfficerMads Krogsgaard Thomsen - Chief Science Officer & Executiv
Mar 08, 2017 - Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.
Mar 02, 2017 - Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International